Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Up 6.8%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXGet Rating)’s share price shot up 6.8% on Wednesday . The company traded as high as $3.28 and last traded at $3.28. 8,425 shares were traded during mid-day trading, a decline of 99% from the average session volume of 690,960 shares. The stock had previously closed at $3.07.

Separately, StockNews.com lowered shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 20th.

The stock has a fifty day simple moving average of $3.68. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.46 and a current ratio of 2.31. The firm has a market capitalization of $1.01 billion, a PE ratio of 153.50, a price-to-earnings-growth ratio of 0.17 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRXGet Rating) last released its earnings results on Wednesday, May 4th. The company reported $0.10 EPS for the quarter, hitting analysts’ consensus estimates of $0.10. Amneal Pharmaceuticals had a net margin of 0.08% and a return on equity of 53.73%. The firm had revenue of $497.63 million during the quarter, compared to analyst estimates of $500.68 million. On average, sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.74 EPS for the current year.

Amneal Pharmaceuticals Company Profile (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Stories

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.